In terms of income and employment, healthcare has become one of India’s most important industries. Hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment are all part of the healthcare industry. The Indian healthcare industry is expanding rapidly as a result of improved coverage, services, and increased spending by both the public and private sectors.
The Indian healthcare system is divided into two categories: public and private. With massive capital investment in modern diagnostic facilities, the country has also become one of the top destinations for high-end diagnostic services, serving a larger part of the population.
Raktim Chattopadhyay founded Esperer Nutrition, a research-based global clinical nutrition company with offices in Mumbai, India, and London, the United Kingdom. The firm is working on dietary treatments for illness prevention and management.
Raktim is the CEO and founder of Esperer Nutrition and has always had a creative streak in his pursuit of all life’s goals. He is an avid reader and storyteller who thinks that the key to solving any problem is in the details and the capacity to think critically about it. He was always keen on pursuing molecular biology in the fields of nutraceutical and cancer science.
Esperer Nutrition
In hypermetabolic conditions, Esperer Nutrition delivers the world’s first research-based condition/stage and cancer/site specific nutrition supplements. It was the first in the world to prioritise medication-nutrient interactions and drug toxicity as significant factors in chronic illness treatment.
Esperer Nutrition Products are designed to satisfy the nutritional needs of cancer patients. The product composition was created with the pre-treatment demands of cancer patients’ normal cells in mind, as well as a direct carbohydrate restriction method to decrease cancer cell growth, making it the first nutritional preconditioning for cancer patients. During cancer therapy (chemo/radiation), the formulation should focus on nutritional balance and making it easier to execute physiological functions of the body while keeping drug-nutrient interactions under control. The EON formulation provides value, especially with its meticulous product design, since the post-cancer treatment recovery period is more sensitive for patients to becoming prone to infection and, therefore, recurrence of disease. All of these formulations ensure a consistent supply of essential nutritional needs for cancer patients, which is crucial for preventing malnutrition-related mortality or cycle decline along the cancer journey.
The EON treatment has been accepted and published by its international patent, establishing it as a unique innovation in the management of nutritional health in cancer disease management as the world’s first condition-specific complementary therapy.
Esperer Nutrition cancer supplements have been carefully created to target specific nutritional interventions for cancer patients, making the product group more valuable as real complemen ts to standard cancer treatment. Esperer’s products, such as Es-Fortitude GH & Es-Fortitude Haemocal target particular cancers such as GI cancer and haematological disorders, improving essential nutrient bio availability, which is commonly impacted by site specific tumours. The products are distinct and targeted because of the site-specific nutritional strategy.
Esperer Nutrition’s cancer series products are designed to help with cancer co-morbid conditions, particularly renal function protection during cancer therapy. Because certain medical conditions as well as medicines used in Cancer therapy alter kidney function, it’s product Ren Voitho intervenes to make renal output desired throughout cancer treatment, keeping the toxicity level below threat level.
Considering cancer wounds are more complex in post-surgery, a special and fast recovery is needed to accelerate the adjuvant chemotherapy. Esperer’s supplement (Liss WH) is designed to speed up the process. This formulation strategy makes the product superior and well ahead of its category.
All of the cancer series products have been tested in Indian and worldwide markets, and are manufactured in a USFDA-approved facility utilising patented global essential ingredients to ensure the quality of the whole range.
‘Pioneering the concept of Clinical Nutrition with its patented understanding of DINI AXIS to manage NCDs & Chronic disorders’
“Our consumer health vertical is EON’s very own therapeutic immunomodulatory research, which offers nutraceutical products to address transmissible components in NCDs.” says Raktim.
Lifestyle diseases refer to all those non-communicable diseases (NCDs) that can develop as a result of hectic and stress prone habits. They depend on the environment you work in, the kind of work you do, the food you eat etc. The most common of these diseases include diabetes, heart disease, stroke, hypertension and cancer not restricted to adults alone, this lifestyle epidemic is spreading amongst kids as well.
The company brings Clinical Nutrition therapy with an evidence- based scientific approach to treat & manage relatively untapped chronic conditions like NCDs with customized solutions to cater to unique consumer need gaps, which will help maintain internal stability through its patented technology.
Its consumer health vertical offers clinical nutrition supplements for NCDs like Hormonal heath, Gut health, Bone & Joint, Urology, Respiratory Conditions, Diabetes, Hepatic, Cardioprotective & General wellness etc.
Challenges are Real Motivation
Raktim says the courage to start a company has come through various rejections of business proposals in his professional career. He goes on to say that the rejections strengthened his convictions about what cancer sufferers require and how an Indian innovation can be implemented on a worldwide scale.
Raktim was raised in a semi-urban area of India, where he was naturally exposed to the country’s diverse cuisine and culture. This gave him enough to think about when he was dealing with the trauma of cancer patients in his professional life. He was motivated to develop an ecosystem with real Indian resources that may symbolise the strength of an Indian’s empathy in business by the reduced quality of life of cancer patients. He recalls, “Since childhood I have seen my father leading a simple life with value-based thinking and trying to do things differently in life, and that has inspired me in every stage of my life. Inherited from family culture, I was always fond of reading and knowing about Swami Vivekananda. His philosophy always inspired me in every act of my life.”
Achieving New Milestones with Every Passing Year
The Indian healthcare industry is extremely diverse, with possibilities in every category, including providers, payers, and medical technology. Since its establishment as a parent business in 2018, Esperer Nutrition has been steadily growing by
onboarding highly skilled individuals as key team members. The company’s marketing and distribution infrastructure is extremely effective and consumer-centric.
In 2019, EON India was formed, and the firm moved forward with product registration, significant R&D investments, and test marketing in India. In 2020, the firm advanced with a few new additions, including strategic investors, a state-of-the-art R&D facility in Hyderabad (ENDC), business expansion and distribution network establishment, and clinical validation of the Onco Nutrition Range.
Esperer Nutrition formed Esperer Nutrition UK Ltd in 2021, adding additional accomplishments such as the start of regulated countries’ registration, the launch of an e-commerce business vertical in consumer care, and the publication of an international patent.
Businesses are seeking the latest dynamics and trends that will have a beneficial influence on their business as the competition grows. From Rs. 4 trillion (US $61.79 billion) in FY17 to Rs. 8.6 trillion (US $121.84 billion) in FY22, India’s hospital sector is expected to grow at a CAGR of 16–17 percent.Top-rated investors are now picking Esperer as a good spot to invest is based on business goals. Raktim states, “When I see Esperer’s innovative products, they bring a smile to the faces of family members of cancer patients.”
Affordable Treatment for Everyone
Malnutrition, according to Raktim, is the underlying cause of NCDs in India, including cancer. In rural India, affordable and accessible cancer infrastructure, from diagnosis to treatment, may significantly improve malnutrition and cancer management. Raktim wants to see his whole business enterprise play a key part in moving the aforementioned objective forward.
Advice for the Emerging Entrepreneurs
Raktim believes that the primary focus for any entrepreneur in the first three years should be repaying the investor’s money. Also, an entrepreneur should concentrate on developing people within the business and allowing others to create the brand, while avoiding short-term distractions. He asserts, “One should have the courage and power to pursue the original intent/purpose of company foundation.”
The CEO
Raktim Chattopadhyay completed his post-secondary studies in the field of physiology, with a focus on medical nutrition. He is also pursuing a PhD in Nutritional Intervention in Liver Carcinoma. Raktim’s optimism and drive are based on the principles of human psychology. He has developed a sympathetic and pragmatic viewpoint through understanding people’s needs and mental frames.
With a deep desire to help people, Raktim founded Esperer Bioresearch (which deals with the manufacturing and marketing of anticancer drugs), Esperer Nutrition (which is a research-based nutraceutical company that is a pioneer in bringing innovative disruption to the cancer nutrition space on a global platform), and Health Voitho Technologies (a company that deals with Artificial Intelligence in disease prevention and early detection). Esperer’s Research and Development team is tackling novel nutra-solutions for various noncommunicable illnesses, including cancer, under Raktim’s strong scientific visionary leadership.
Raktim’s innovative “DINI AXIS” hypothesis (global patent status) in this context is being well appreciated in recent days by various domestic and global platforms. Within a very short period of time, Esperer has taken a global fly and even established its branch in London, UK as Esperer Nutrition UK Ltd. Raktim has made several international allies in the field of cancer through marketing, distribution, research, and manufacturing.
To add to that, Raktim has over 20 years of extensive technological and commercial expertise in the healthcare industry, offering a comprehensive understanding of different business factors that improve business outcomes. In his more than 14 years as a leader, he has successfully accomplished company turnarounds, developed start-up subsidiary operations for hyper-specialised areas, been key in smoother team reorganisation, and managed P&L obligations for big accounts. Raktim has worked with firms such as Wockhardt, Cadila, and others in his professional career. Raktim has been asked to speak as an industry expert at numerous development forums across the world. Raktim has received various awards from domestic and international forums for his contributions to business and science.
